-
3 weeks ago | 
contagionlive.com | Sophia Abene |Anu Osinusi
A Phase 1a study in New Zealand evaluated the safety, tolerability, and immunogenicity of two novel arenaviral vectored vaccines, GS-2829 and GS-6779, for hepatitis B virus (HBV) infection. The study enrolled 51 healthy participants, aged 33 on average, who received varying doses of the vaccines via intramuscular administration to assess safety and immune response. The results were presented at the 2025 International Liver Congress (EASL).
-
3 weeks ago | 
contagionlive.com | Sophia Abene |Anu Osinusi
A multinational real-world study of 7,027 patients treated with sofosbuvir/velpatasvir (SOF/VEL) for hepatitis C virus (HCV) infection reported a sustained virologic response (SVR) rate of 98.9%. "We're really excited to share this data at EASL this year," said Anu Oshinusi, MD, MPH, vice president of clinical research for hepatitis, respiratory, and emerging viruses at Gilead Sciences.
-
4 weeks ago | 
contagionlive.com | John Parkinson |Anu Osinusi
In a late-breaking oral presentation at EASL, 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) who were treated with the first-in-class entry inhibitor bulevirtide, at either a 2 mg or 10 mg dose, maintained virologic suppression for nearly 2 years after treatment, following undetectable HDV RNA when they finished their treatment. These findings were part of Gilead’s phase 3 MYR301 trial.
-
4 weeks ago | 
contagionlive.com | John Parkinson |Anu Osinusi
At the ongoing European Association for the Study of the Liver (EASL) Congress 2025, Gilead announced findings on its hepatitis D (HDV) therapy, bulevirtide. Specifically, the therapy was studied as a standalone treatment and in combination with pegylated interferon alpha (PegIFN).
-
Jun 11, 2024 | 
healio.com | Kate Burba |Anu Osinusi
-
Jun 7, 2024 | 
healio.com | Anu Osinusi |Kate Burba |Heather Biele
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Study results suggest that combination bulevirtide 10 mg with PEG-IFN a-2a was superior to bulevirtide monotherapy in achieving undetectable HDV RNA. Results were sustained through week 48 of treatment.
-
Jun 5, 2024 | 
kevinmd.com | Anu Osinusi |Angel Garcia Otano |Sharona Hoffman |Casey Paul Schukow
This article is sponsored by Sunoh.ai, a revolutionary AI-powered ambient listening technology for clinical documentation. The integration of artificial intelligence (AI) within health care is one of, if not the most significant, health care industry development in recent history. AI is a powerful solution that provides significant benefits from across the practice to patient care, providers, and administrative staff.
-
Apr 1, 2024 | 
kevinmd.com | Anu Osinusi |John Pagel |Bob Bhayani |Kathryn Crofton
This article is sponsored by Pattern. I discussed disability insurance with Pattern advisor Shelby Heiser to discuss how it is more than a box that doctors need to check—it’s a tool for financial security and peace of mind. Each physician is unique. They come from different backgrounds, work in different specialties, and serve an immeasurable amount of patients, each with their own needs. But every physician has one thing in common: A need to: protect their income.
-
Mar 25, 2024 | 
kevinmd.com | Anu Osinusi |John Pagel |Steven Siegel |George Mathew
This article is sponsored by Nuance Communications, a technology pioneer with market leadership in conversational, ambient, and generative AI. A full-service partner trusted by 77 percent of U.S. hospitals and more than 75 percent of Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people’s ability to help others. Nuance is a Microsoft company.
-
Jan 29, 2024 | 
kevinmd.com | Anu Osinusi |John Pagel |Gary Call |Janet Tamaren
This article is sponsored by the Centers for Disease Control and Prevention. Pain is a deeply personal experience and one of the most common reasons why individuals seek medical care in the U.S. The Centers for Disease Control and Prevention (CDC) recognizes the challenges both clinicians and patients face with pain management and the risks associated with opioid prescribing.
